Table 3.

Predictors of metastases^*

Variable	HR	95% CI	p
Univariable analysis
ADT PSA nadir relative to undetectable
0.01–0.2 ng/ml	3.04	1.19–7.76	0.020
>0.2 ng/ml	16.50	8.33–32.70	<0.001
ADT PSA nadir, continuous	2.29	1.68–3.13	<0.001
Pre-ADT PSA, log-transformed	1.72	1.38–2.14	<0.001
Black race	0.78	0.40–1.53	0.471
Extracapsular extension	1.07	0.58–1.98	0.823
Seminal vesicle invasion	2.14	1.16–3.93	0.014
Surgical margin status	0.94	0.49–1.79	0.852
Pathologic Gleason sum relative to 2–6
7	0.59	0.20–1.73	0.335
8–10	2.88	1.11–7.49	0.030
Age at the start of ADT	0.98	0.94–1.02	0.382
Calendar year of RP	0.98	0.92–1.05	0.626
Lymph node metastases	2.08	0.80–5.40	0.131
Time to ADT nadir	1.01	0.96–1.05	0.757
Salvage external-beam radiation therapy	1.31	0.71–2.42	0.393
PSA persistence after RP	1.25	0.63–2.49	0.520
Multivariable analysis using PSA nadir ADT as a continuous variable
PSA nadir ADT	1.64	1.17–2.29	0.004
Pre-ADT PSA, log-transformed	1.73	1.33–2.25	<0.001
Seminal vesicle invasion	1.92	1.02–3.64	0.045
Gleason sum 8–10 relative to 2–6	1.56	0.58–4.18	0.374
Multivariable analysis using PSA nadir ADT as a categorical variable
PSA nadir ADT relative to undetectable
0.01–0.2 ng/ml	3.98	1.50–10.55	0.006
>0.2 ng/ml	12.42	5.85–26.37	<0.001
Pre-ADT PSA, log-transformed	1.61	1.20–3.84	0.002
Seminal vesicle invasion	2.00	1.04–3.84	0.038
Gleason sum 8–10 relative to 2–6	2.02	0.75–5.39	0.163

HR = hazard ratio; CI = confidence interval; ADT = androgen-deprivation therapy; PSA = prostate-specific antigen; RP = radical prostatectomy.

^*n = 294; events = 42.